Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

ConclusionCombination therapy was safe and tolerable and displayed favorable PK. The MTD was established at galunisertib at 150  mg orally twice a day and ramucirumab 8 mg/kg intravenously every 2 weeks. The results do not support the preclinical hypothesis that blocking TGFβ signaling enhances efficacy of VEGF‐targeted therapy; thus further clinical development was halted for the combination of galunisertib and ramuci rumab.

Source: Cancer Medicine - April 3, 2021 Category: Cancer & Oncology Authors: James J. Harding, Richard K. Do, Amin Yaqubie, Ann Cleverly, Yumin Zhao, Ivelina Gueorguieva, Michael Lahn, Karim A. Benhadji, Robin K. Kelley, Ghassan K. Abou ‐Alfa Tags: ORIGINAL RESEARCH Source Type: research